Neurocrine Biosciences Newsroom

Maintaining Hold on Neurocrine Biosciences Amid Efficacy Concerns and Competitive Pressures

TipRanksJul 2 09:32

Neurocrine Biosciences Analyst Ratings

BenzingaJun 13 01:05

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Maintains $160 Price Target

BenzingaJun 13 01:04

Neurocrine Biosciences Analyst Ratings

BenzingaMay 29 20:35

Neurocrine Biosciences Analyst Ratings

BenzingaMay 28 20:11

UBS: Maintaining the Neurocrine Biosciences (NBIX.US) rating, adjusted from buy to buy rating, and adjusted the target price from $174.00 to $193.00.

Zhitong FinanceMay 28 20:11

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $193

BenzingaMay 28 20:10

Neurocrine Biosciences (NBIX.US) was first covered by Evercore ISI Group, which gave it an superior market rating, with a target price of $175.00.

Zhitong FinanceMay 14 17:21

Neurocrine Biosciences Analyst Ratings

BenzingaMay 14 17:20

Evercore ISI Group Initiates Coverage On Neurocrine Biosciences With Outperform Rating, Announces Price Target of $175

BenzingaMay 14 17:20

Neurocrine Biosciences Analyst Ratings

BenzingaMay 4 06:05

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $164

BenzingaMay 3 03:20

Neurocrine Biosciences Analyst Ratings

BenzingaMay 3 02:05

Barclays: Maintaining the Neurocrine Biosciences (NBIX.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $150.00 to $169.00.

Zhitong FinanceMay 3 02:01

UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating

MT NewswiresMay 2 23:20

Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $216

BenzingaMay 2 21:00

Oppenheimer Sticks to Its Buy Rating for Neurocrine (NBIX)

TipRanksMay 2 20:10

HC Wainwright & Co. : The Neurocrine Biosciences (NBIX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $150.00 to $160.00.

Zhitong FinanceMay 2 19:00

Buy Rating Affirmed for Neurocrine Biosciences on Strong Performance and Promising Pipeline

TipRanksMay 2 12:01

Needham: Reiterates that Neurocrine Biosciences (NBIX.US) holds the rating.

Zhitong FinanceMay 1 23:50